CELLECTIS Aktie

5,79 EUR -0,1724%

Zu Ihrem Onlinebroker

kaufen verkaufen

CELLECTIS Aktienkurs : 25.05. ( 15 Min. verzögert)
5,79 € Letzter Kurs	-0,17% Veränderung	5,80 € Vortag	5,80 € Eröffnungskurs

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
5,80 - 5,72 Tag	9,15 - 5,53 52 Wochen	1.459 Tag	14.087 Ø 52 Wochen	0,0000000 0 Stücke	0,0000000 0 Stücke

CELLECTIS Aktienkurs

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

23.05.

French biotechs afflicted by a plunge in financial support

... in France in terms of products in phase 2 and 3," noted André Choulika, the France Biotech president and CEO of Cellectis, according to Nature. "The total number of these products is now equal to a top ten ...
23.05.

French biotech sector struggling

... products in phase 2 and 3,” says André Choulika, France Biotech president and co-founder, chairman and chief executive of genomic-engineering firm Cellectis. “The total number of these products is ...

22.05.

Cellectis stem cells today proudly announces the launch of the world's very ...

GOTHENBURG, Sweden--(EON: Enhanced Online News)--Cellectis stem cells, a Business Unit of Cellectis Group (Alternext: ALCLS), a premier provider of stem cell derived products and technologies,...
21.05.

Cellectis stem cells today proudly announces the launch of the world's very ...

Cellectis stem cells, a Business Unit of Cellectis Group (alternext:ALCLS), a premier provider of stem cell derived products and technologies, today announces the launch of a human iPS...
11.05.

Medicago Announces 2012 First Quarter Financial Results

... completing the fourth milestone related to the DARPA project, initiating a research collaboration with Cellectis, and moving ahead with our internal rabies vaccine candidate," said Andy Sheldon, President and Chief Executive Officer of Medicago.